Last update 29 Aug 2025

Shanghai Xianxiang Medical Technology Co., Ltd.

Subsidiary Company|2022|Shanghai Shi, China

Overview

Basic Info

Introduction
Shanghai Xianshang Pharmaceutical Technology Co., Ltd. operates as a subsidiary under the larger umbrella of Xiansheng Pharmaceuticals. This entity was established in September 2022 and primarily concentrates on the development in areas such as oncology, neurology, autoimmune diseases, and anti-infective treatments.

Tags

Neoplasms
Hemic and Lymphatic Diseases
Immune System Diseases
Trispecific T-cell engager (TriTE)
Antibody drug conjugate (ADC)
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms6
Hemic and Lymphatic Diseases1
Immune System Diseases1
Endocrinology and Metabolic Disease1
Top 5 Drug TypeCount
Small molecule drug2
Antibody drug conjugate (ADC)2
Trispecific T-cell engager (TriTE)1
Fusion protein1
Top 5 TargetCount
FGFR2 x FGFR2b x Top I1
BCMA x CD3 x GPRC5D1
POLQ(DNA polymerase theta)1
USP1(ubiquitin specific peptidase 1)1
IL-15 x PDL11

Related

6
Drugs associated with Shanghai Xianxiang Medical Technology Co., Ltd.
SIM-0501
Target
USP1
Mechanism
USP1 inhibitors
Active Org.
Nanjing Simcere Dongyuan Pharmaceutical Co. Ltd.Nanjing Simcere Dongyuan Pharmaceutical Co. Ltd. [+2]
Originator Org.
Simcere Pharmaceutical Group Ltd.Simcere Pharmaceutical Group Ltd.
Active Indication
Advanced Malignant Solid Neoplasm [+1]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
SIM-0500
Target
BCMA x CD3 x GPRC5D
Mechanism
BCMA inhibitors [+2]
Active Org.
Shanghai Xianxiang Medical Technology Co., Ltd.
Originator Org.
Simcere Pharmaceutical Group Ltd.Simcere Pharmaceutical Group Ltd.
Active Indication
Refractory Multiple Myeloma [+2]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
SIM-0686
Target
FGFR2 x FGFR2b x Top I
Mechanism
FGFR2 antagonists [+2]
Active Org.
Simcere Pharmaceutical Group Ltd.Simcere Pharmaceutical Group Ltd. [+2]
Originator Org.
Nanjing Simcere Dongyuan Pharmaceutical Co. Ltd.Nanjing Simcere Dongyuan Pharmaceutical Co. Ltd.
Active Indication
FGFR2 Mutation Solid Tumors [+2]
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
7
Clinical Trials associated with Shanghai Xianxiang Medical Technology Co., Ltd.
NCT06792552
/ RecruitingPhase 1
A Phase I First-in-human, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants With Advanced Solid Tumors
NCT06686745
/ RecruitingPhase 1
A Phase I, First-in-Human, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0508 Monotherapy and Combination Therapy in Adult Participants With Locally Advanced/Metastatic Solid Tumors
NCT06375044
/ RecruitingPhase 1
A Phase I First-in-human, Open-label Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0500, A Humanized GPRC5D-BCMA-CD3 Tri-specific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma
100 Clinical Results associated with Shanghai Xianxiang Medical Technology Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Shanghai Xianxiang Medical Technology Co., Ltd.
Login to view more data
100 Deals associated with Shanghai Xianxiang Medical Technology Co., Ltd.
Login to view more data
100 Translational Medicine associated with Shanghai Xianxiang Medical Technology Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 Sep 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
IND Approval
2
6
Phase 1
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free